mevastatin has been researched along with Hypercholesterolemia in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (50.00) | 18.7374 |
| 1990's | 4 (25.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alberts, AW; Bostedor, R; Chao, YS; Duggan, ME; Fitzpatrick, SL; Halczenko, W; Hartman, GD; Imagire, JS; Pitzenberger, SM; Smith, RL | 1 |
| Bjune, K; Leren, TP; Naderi, S; Sundvold, H | 1 |
| Averna, M; Blom, D; Cefalù, AB; Ciccarese, M; Cossu, M; Croyal, M; Dallinga-Thie, G; Guédon, A; Hovingh, K; Lambert, G; Passard, M; Peter, J; Pintus, P; Pisciotta, L; Prampart-Fauvet, S; Raal, F; Santos, RD; Sjouke, B; Thedrez, A | 1 |
| Endo, A; Sudo, H; Yammoto, A | 1 |
| George, J; Keren, G; Luboshits, G; Mausner-Fainberg, K; Maysel-Auslender, S; Mor, A; Rubinstein, A | 1 |
| Nakamura, N; Uzawa, H; Yamaguchi, K | 1 |
| Bosisio, E; Cighetti, G; Di Padova, C; Galli Kienle, M; Galli, G; Paoletti, R; Rovagnati, P | 1 |
| Fears, R; Ferres, H; Richards, DH | 1 |
| Endo, A; Sudo, H; Yamamoto, A | 1 |
| al Rayyes, O; Florén, CH; Wallmark, A | 1 |
| Mabuchi, H | 1 |
| Endo, A; Kuroda, M; Tanzawa, K; Tsujita, Y | 1 |
| Endo, A | 1 |
| Tobert, JA | 1 |
| Santafé Oroz, J; Segarra Domènech, J | 1 |
4 review(s) available for mevastatin and Hypercholesterolemia
| Article | Year |
|---|---|
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Lactation; Lipoproteins; Lovastatin; Naphthalenes; Niacin; Pentanoic Acids; Pregnancy; Pregnancy Complications; Probucol; Tangier Disease; Triglycerides | 1984 |
[Clinical studies on hyperlipidemia].
Topics: Acyl Coenzyme A; Anticholesteremic Agents; Blood Component Removal; Clinical Trials as Topic; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin | 1999 |
The discovery and development of HMG-CoA reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; History, 20th Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin | 1992 |
[Pharmacologic therapy of arteriosclerosis. II. New directions].
Topics: Animals; Anticholesteremic Agents; Arachidonate Lipoxygenases; Arteriosclerosis; Blood Platelets; Cholesterol; Cholesterol Esters; Cholesterol, LDL; Enzyme Induction; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoxygenase Inhibitors; Lovastatin; Male; Models, Biological; Muscle, Smooth, Vascular; Naphthalenes; Phosphatidylcholine-Sterol O-Acyltransferase; Platelet Aggregation; Rats; Receptors, LDL | 1985 |
1 trial(s) available for mevastatin and Hypercholesterolemia
| Article | Year |
|---|---|
New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Clinical Trials as Topic; Dogs; Double-Blind Method; Drug Evaluation; Drug Tolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipoproteins, HDL; Lipoproteins, VLDL; Lovastatin; Middle Aged; Naphthalenes; Pravastatin; Simvastatin; Triglycerides | 1987 |
11 other study(ies) available for mevastatin and Hypercholesterolemia
| Article | Year |
|---|---|
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 9. The synthesis and biological evaluation of novel simvastatin analogs.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Disease Models, Animal; Dogs; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Magnetic Resonance Spectroscopy; Rats; Simvastatin; Structure-Activity Relationship | 1992 |
MK-2206, an allosteric inhibitor of AKT, stimulates LDLR expression and LDL uptake: A potential hypocholesterolemic agent.
Topics: Anticholesteremic Agents; Biological Transport; Cholesterol, LDL; HeLa Cells; Hep G2 Cells; Hepatocytes; Heterocyclic Compounds, 3-Ring; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Protein Kinase Inhibitors; Proteolysis; Proto-Oncogene Proteins c-akt; Receptors, LDL; Signal Transduction; Sterol Regulatory Element Binding Protein 2 | 2018 |
Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Case-Control Studies; Cells, Cultured; Cholesterol, LDL; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type III; Lovastatin; Lymphocytes; Male; Middle Aged; Mutation; PCSK9 Inhibitors; Phenotype; Proprotein Convertase 9; Receptors, LDL; Serine Proteinase Inhibitors; Young Adult | 2016 |
Therapeutic effects of ml-236B in primary hypercholesterolemia. 1980.
Topics: History, 20th Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin | 2004 |
The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells.
Topics: Adult; Animals; Atorvastatin; Forkhead Transcription Factors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Mice; Mice, Inbred C57BL; Pravastatin; Pyrroles; T-Lymphocytes, Regulatory; Up-Regulation | 2008 |
Blocking 3-hydroxy-3-methylglutaryl coenzyme A reductase with ML-236B enhances the plasma cortisol response to adrenocorticotropin in patients with hypercholesterolemia.
Topics: Adrenocorticotropic Hormone; Anticholesteremic Agents; Female; Humans; Hydrocortisone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Naphthalenes | 1984 |
Effects of compactin (ML-236 B) on biliary lipid composition and cholesterol catabolism in the hamster.
Topics: Animals; Anticholesteremic Agents; Bile; Body Weight; Cholesterol; Cricetinae; Diet; Hypercholesterolemia; Lipid Metabolism; Liver; Lovastatin; Mesocricetus; Naphthalenes; Organ Size | 1982 |
The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks.
Topics: Animals; Anticholesteremic Agents; Chickens; Cholesterol; Cholestyramine Resin; Circadian Rhythm; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, VLDL; Lovastatin; Male; Naphthalenes; Rats | 1980 |
Therapeutic effects of ML-236B in primary hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Child, Preschool; Cholesterol; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Naphthalenes | 1980 |
Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Topics: Anticholesteremic Agents; Biological Transport, Active; Cyclosporine; Down-Regulation; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipoproteins, LDL; Lovastatin; Receptors, LDL; Tumor Cells, Cultured; Up-Regulation | 1997 |
Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals.
Topics: Animals; Anticholesteremic Agents; Bile Acids and Salts; Cholesterol; Cholesterol, Dietary; Feces; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Hyperlipidemias; Liver; Lovastatin; Male; Mice; Naphthalenes; Polyethylene Glycols; Rats; Species Specificity; Sterols | 1979 |